About peptidream inc - PPTDF
PeptiDream, Inc. engages in the biopharmaceutical business that includes research and development of non-standard peptide therapeutics. It operates through Drug Discovery and Development Business segment. The Drug Discovery and Development Business segment provides macrocyclic peptides based on its proprietary Peptide Discovery Platform System (PDPS) and engages in collaborative drug discovery research and development, technology licensing of PDPS, and expansion of pipeline through strategic alliances. The company was founded by Kiichi Kubota and Hiroaki Suga on July 3, 2006 and is headquartered in Kawasaki, Japan.
PPTDF At a Glance
PeptiDream Inc.
3-25-23 Tonomachi
Kawasaki, Kanagawa 210-0821
| Phone | 81-44-270-1300 | Revenue | 123.81M | |
| Industry | Biotechnology | Net Income | -25,061,605.23 | |
| Sector | Health Technology | Employees | 645 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
PPTDF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 11.038 |
| Price to Book Ratio | 4.154 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -68.688 |
| Enterprise Value to Sales | 10.562 |
| Total Debt to Enterprise Value | 0.095 |
PPTDF Efficiency
| Revenue/Employee | 191,946.42 |
| Income Per Employee | -38,855.202 |
| Receivables Turnover | 3.057 |
| Total Asset Turnover | 0.227 |
PPTDF Liquidity
| Current Ratio | 1.662 |
| Quick Ratio | 1.526 |
| Cash Ratio | 1.225 |
PPTDF Profitability
| Gross Margin | 38.865 |
| Operating Margin | -26.858 |
| Pretax Margin | -28.459 |
| Net Margin | -20.243 |
| Return on Assets | -4.59 |
| Return on Equity | -7.265 |
| Return on Total Capital | -5.534 |
| Return on Invested Capital | -6.163 |
PPTDF Capital Structure
| Total Debt to Total Equity | 37.752 |
| Total Debt to Total Capital | 27.406 |
| Total Debt to Total Assets | 25.006 |
| Long-Term Debt to Equity | 3.784 |
| Long-Term Debt to Total Capital | 2.747 |